Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 06, 2015 12:09 PM ET

Biotechnology

Company Overview of Idera Pharmaceuticals, Inc.

Company Overview

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for oncology and rare diseases in the United States. It uses two proprietary drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and gene silencing oligonucleotide (GSO) technology. The company’s lead drug candidate includes IMO-8400, which is in Phase 1/2 clinical trials for the treatment of Waldenström’s Macroglobulinemia, diffuse large B-cell lymphoma, and Duchenne muscular dystrophy, as well as in Phase 2 clinical trial for the treatment of dermatomyositis. Its p...

167 Sidney Street

Cambridge, MA 02139

United States

Founded in 1989

45 Employees

Phone:

617-679-5500

Fax:

617-679-5592

Key Executives for Idera Pharmaceuticals, Inc.

Chief Executive Officer and Director
Age: 50
Total Annual Compensation: $50.0K
Chief Financial Officer, Senior Vice President of Operations, Treasurer and Secretary
Age: 53
Total Annual Compensation: $425.9K
President of Research and Director
Age: 60
Total Annual Compensation: $856.4K
Compensation as of Fiscal Year 2014.

Idera Pharmaceuticals, Inc. Key Developments

Idera Pharmaceuticals, Inc. Announces FDA Orphan Drug Designation for IMO-8400 for the Treatment of Diffuse B-Cell Lymphoma

Idera Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for IMO-8400, an antagonist of the endosomal Toll-like receptors (TLRs) 7, 8 and 9, for the treatment of diffuse large B-cell lymphoma (DLBCL). Idera is currently conducting a clinical trial of IMO-8400 in patients with relapsed or refractory DLBCL harboring MYD88 L265P oncogenic mutation. Preclinical studies have shown that in B-cell lymphomas characterized by the MYD88 L265P oncogenic mutation, including DLBCL, TLR signaling is over-activated, thereby enabling tumor cell survival and proliferation. As a TLR antagonist, IMO-8400 inhibits TLR signaling. The objectives of the trial are to evaluate the compound's safety, tolerability and clinical activity. The protocol includes three dose-escalation cohorts of IMO-8400 administered subcutaneously.

Idera Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 01:40 PM

Idera Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 01:40 PM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Vincent J. Milano, Chief Executive Officer and Director.

Idera Pharmaceuticals, Inc. Announces Resignation of Louis Brenner as Senior Vice President and Chief Medical Officer, Effective April 3, 2015

On March 17, 2015, Louis Brenner, M.D. resigned his positions as Senior Vice President and Chief Medical Officer of Idera Pharmaceuticals, Inc. to accept a new role as the Chief Operating Officer of a privately-held biotechnology company. This change will become effective April 3, 2015.

Similar Private Companies By Industry

Company Name Region
Chiragene United States
ZLB Bioplasma, Inc. United States
Circulating Tumor Cell Inc. United States
Recombinetics, Inc. United States
HB Custom Media, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Idera Pharmaceuticals, Inc., please visit www.iderapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.